ATHIRA PHARMA, INC.

(ATHA)
  Report
Delayed Nasdaq  -  04:00 2022-08-15 pm EDT
3.900 USD    0.00%
08/15ATHIRA PHARMA : Corporate Presentation August 2022
PU
08/15ATHIRA PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/15ATHIRA PHARMA : Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Decline Premarket Wednesday

06/22/2022 | 09:24am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ATHIRA PHARMA, INC. 0.00% 3.9 Delayed Quote.-70.07%
BRIDGEBIO PHARMA, INC. -0.34% 11.56 Delayed Quote.-30.70%
ENANTA PHARMACEUTICALS, INC. 3.63% 70.46 Delayed Quote.-5.78%
NASDAQ COMPOSITE 0.62% 13128.05 Real-time Quote.-16.60%
PFIZER, INC. -0.72% 49.75 Delayed Quote.-15.75%
All news about ATHIRA PHARMA, INC.
08/15ATHIRA PHARMA : Corporate Presentation August 2022
PU
08/15ATHIRA PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/15ATHIRA PHARMA : Reports Second Quarter 2022 Financial Results and Recent Clinical and Corp..
PU
08/15ATHIRA PHARMA, INC. : Results of Operations and Financial Condition, Regulation FD Disclos..
AQ
08/15Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Cor..
GL
08/15Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Cor..
GL
08/03Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosg..
GL
08/03Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosg..
AQ
08/03Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosg..
CI
08/02Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Co..
GL
More news
Analyst Recommendations on ATHIRA PHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -101 M - -
Net cash 2022 160 M - -
P/E ratio 2022 -1,47x
Yield 2022 -
Capitalization 147 M 147 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 35
Free-Float 94,9%
Chart ATHIRA PHARMA, INC.
Duration : Period :
Athira Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATHIRA PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,90 $
Average target price 10,10 $
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Mark J. Litton President, Chief Executive Officer & Director
Glenna Mileson Chief Financial Officer
Kelly A. Romano Chairman
Hans Moebius Chief Medical Officer
Lawrence E. Chun Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ATHIRA PHARMA, INC.-70.07%147
MODERNA, INC.-30.40%66 966
IQVIA HOLDINGS INC.-12.01%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.9.01%31 380
ALNYLAM PHARMACEUTICALS, INC.36.22%28 068